

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED
JUN 21 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

TECH CENTER 1600/290
7/2

Crabtree et al.

Serial No: 10/040,430

Filed: January 7, 2002

For: NF-AT Polypeptides and
Polynucleotides and Screening Methods
for Immunosuppressive Agents

Attorney Docket No. APBI-P05-008

Art Unit: 1656

Examiner: N/A

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231.

6/7/02
Date of Signature
and of Mail Deposit

Anna P. Lucey

Anna P. Lucey

Commissioner for Patents
United State Patent and Trademark Office
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT IN COMPLIANCE WITH 37
CFR §§ 1.97(b) and 1.98(d)**

Submitted herewith on Form PTO-1449 is a list of publications that applicants and their agents/attorneys have identified during the preparation of this application. In accordance with CFR § 1.98 (d), applicants respectfully submit that *no copy* of any patent, publication, or other information listed on the enclosed Form PTO 1449 is needed because the citations were made in prior application U.S.S.N. 09/232,346, filed January 15, 1999 which is relied upon for an earlier filing date under 35 U.S.C. 120.

This Information Disclosure Statement is being filed before the mailing of the first office action on the merits; therefore, no fee is due.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form 1449.


This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Information Disclosure Statement submitted herewith is being filed before the mailing date of a first Office Action on the merits, and as such applicants believe no fees are due at this time. However, should any fees need to be paid in connection with this submission, the Commissioner is hereby authorized to credit any overpayment or charge any deficiency to/from **Deposit Account No. 18-1945**, under Order No. APBI-P05-008.

Respectfully submitted,
Ropes & Gray

By:


Matthew P. Vincent
Reg. No. 36,709

Dated:
Customer No. 28120
Ropes & Gray
Patent Group
One International Place
Boston, MA 02110-2624

Form PTO-1449

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**
(Use several sheets if necessary)

JUN 17 2002

Docket Number (Optional)
APBI-P05-008Application Number
10/040,430Applicant
Crabtree et al.Filing Date
January 7, 2002Group Art Unit
1656**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA 6,171,781	1/9/01	Crabtree et al.			
	AB 6,150,099	11/21/00	Crabtree et al.			
	AC 6,096,515	8/1/00	Crabtree et al.			
	AD 5,837,840	11/17/98	Crabtree et al.			JUN 21 2002
	AE 5,656,452	8/12/97	Rao et al.			

RECEIVED

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	Translation	
	AF	WO 95/08554		PCT			YES	NO
COPY OF PAPERS ORIGINALLY FILED	AG	WO 95/02053	1/19/95	PCT				
	AH	WO 94/15964	7/21/94	PCT				
	AI	WO 93/04203	3/4/93	PCT				

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

	AJ	Arai et al. U. S. Application No. 08/148,061 filed 11/5/93.
	AK	Arai et al. U. S. Application No. 08/113,971 filed 8/30/93.
	AL	Arai et al. U. S. Application No. 08/099,998 filed 7/30/93.
	AM	Arai et al. U. S. Application No. 08/088,483 filed 7/6/93.
	AN	Banerji, S. et al. The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. <i>Mol. Cell. Biol.</i> 11, 4074-4087 (1991).
	AO	Bierer, B. et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. <i>PNAS</i> 87, 9231-9235 (1990).
	AP	Clipstone, N. & Crabtree, G. Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. <i>Ann. N. Y. Acad. Sci.</i> 696, 20-30 (1993).
	AQ	Clipstone, N. & Crabtree, G. Identification of calcineurin as a key signaling enzyme in lymphocyte activation. <i>Nature</i> 357, 695-697 (1992).
	AR	Crabtree, G. Contingent genetic regulatory events in T lymphocyte activation. <i>Science</i> 243, 355-361 (1989).

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number (Optional) APBI-P05-008	Application Number 10/040,430
		Applicant Crabtree et al.	JUN 17 2002 P A T E N T & T R A D E M A R K O F F I C E
		Filing Date January 7, 2002	Group Art Unit 1656
			RECEIVED
AS	Crabtree, G. Pathways of T lymphocyte activation. <i>Abstract of NIH Grant No. R01CA39612</i> (1998). JUN 21 2002		
AT	Crabtree, G. Pathways of T lymphocyte activation. <i>Abstract of NIH Grant No. R01CA39612</i> (1998). TECH CENTER 1600/2900		
AU	Crabtree, G. & Clipstone, N. Signal transmission between plasma membrane and nucleus of T lymphocyte. <i>Ann. Rev. Biochem.</i> 63, 1045-1083 (1994).		
AV	Durand, D. et al. Characterization of antigen receptor response elements within the interleukin-2 enhancer. <i>Mol. Cell. Biol.</i> 8, 1715-1724 (1988).		
AW	Emmel, E. et al. Nuclear association of a T-Cell transcription factor blocked by FK-506 and cyclosporin A. <i>Nature</i> 352, 803-807 (1991).		
AX	Flanagan, W. et al. Nuclear association of a T-cell transcription factor blocked by FK506 and cyclosporin A. <i>Nature</i> 352, 803-807 (1991).		
AY	Ho, S. et al. Cloning and characterization of NF-ATc and NF-ATp: the cytoplasmic components of NF-AT. <i>Adv. Exp. Med. Biol.</i> 365, 167 (1994).		
AZ	Israel, A. NF-AT comes under control. <i>Nature</i> 369, 443-444 (1994).		
BA	Jain et al. Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. <i>J. Immunol.</i> 151, 837-848 (1993).		
BB	Jain, J. et al. Nuclear factor of activated T cells contains Fos and Jun. <i>Nature</i> 356, 801-804 (1992).		
BC	Jain et al. The T cell transcription factor NF-ATp is a substrate for calcineurin and interacts with Fos and Jun. <i>Nature</i> 365, 352-355 (1993).		
BD	Jin, Y. et al. Molecular cloning of a membrane-associated human FK-506 and rapamycin-binding protein FKBP-13. <i>PNAS</i> 88, 6677-6681 (1991).		
BE	Matilla, P. et al. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. <i>EMBO J.</i> 9, 4425-4433 (1990).		
BF	McCaffrey et al. Isolation of the cyclosporin-sensitive T cell transcription factor NF-ATp. <i>Science</i> 262, 750-754 (1993).		
BG	McCaffrey et al. NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. <i>J. Biol. Chem.</i> 268, 3747-3752 (1993).		
BH	Northrop et al. Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NF-AT) complex. <i>J. Biol. Chem.</i> 268, 2917-2923 (1993).		
BI	Northrop et al. NF-AT components define a family of transcription factors targeted in T-Cell Activation. <i>Nature</i> 369, 497-502 (1994).		

**COPY OF PAPERS
ORIGINALLY FILED**

• Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) APBI-P05-008	Application Number 10/040,430
		Applicant Crabtree et al.	JUN 17 2002 U.S. PATENT AND TRADEMARK OFFICE RECEIVED OCT 1 2002 GROUP ART UNIT 1656
		Filing Date January 7, 2002	
	BJ	Rao, A. NF-AT: a transcription factor required for the co-ordinate induction of several cytokine genes. <i>Immunology Today</i> 15, 274-281 (1994).	
	BK	Rao et al. U.S. Application No. 08/145,006, filed 5/11/93.	
	BL	Rao et al. U.S. Application No. 08/017,052 filed 2/11/93.	
	BM	Rao et al. U. S. Application No. 08/006,067 filed 1/15/93.	
	BN	Riegel, J. et al. Nuclear Events after activation of CD4+8+ thymocytes. <i>J. Immunol.</i> 144, 6-3611-3618 (1990).	
	BO	Shaw, J. et al. Identification of a putative regulator of early T cell activation genes. <i>Science</i> 241, 202-225 (1988).	
	BP	Schmidt, A. et al. Inducible Nuclear Factor Binding to the kB elements of the human immunodeficiency virus enhancer in T cells can be blocked by cyclosporin A in a signal-dependent manner. <i>J. Virology</i> 64, 4037-4041 (1990).	
	BQ	Schreiber, S. Chemistry and biology of the immunophilins and their immunosuppressive ligands. <i>Science</i> 251, 283-287 (1991).	
	BR	Verweij, C. et al. Cell type specificity and activation requirements for NF-AT-1 (Nuclear Factor of Activated T-cells) transcriptional activity determined by a new method using transgenic mice to assay transcriptional activity of an individual nuclear factor. <i>J. Biol. Chem.</i> 265, 15788-15795 (15 September 1990).	
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

JUN 21 2002

TECH CENTER 1600/2900